Description of Invention:
The NIH announces a new technology that relates to compounds that possess potent androgenic activity. These compounds include 7-alpha, 11-beta-dimethyl-17-beta-hydroxyestra-4,14-dien-3-one and 17 esters thereof, and 7-alpha,11-beta-dimethyl-17-beta-hydroxyestra-4-en-3-one 17-undecanoate. These compounds offer a potential therapeutic benefit in the treatment of hypogonadism, regardless of cause, as an adjuvant in hormone replacement therapy for both men and women and for androgen stimulation of anabolism in a broad spectrum of disease entities involving debilitation.
These compounds exhibit both oral and parenteral androgenic activity. Oral activity appears greater than that of methyltestosterone. Parenteral activity as an aqueous suspension is substantially longer than that produced by testosterone enanthate or testosterone cypionate. Since these compounds lack a 17-alkyl moiety, they are expected to show less hepatotoxicity upon oral administration. Claims in this patent application are drawn to the new androgenic compounds themselves, their method of preparation, pharmaceutical formulations containing the new androgens and their utility and use in a wide spectrum of therapeutic applications.
Inventors:
Drs. Richard Blye and H.K. Kim (NICHD)
Patent Status:
DHHS Reference No. E-069-2000/2 --
U.S. Patent Application No. 11/040,964 filed 21 Jan 2005
DHHS Reference No. E-069-2000/3 --
U.S. Patent 7,196,074 issued 27 Mar 2007
Foreign counterparts pending or issued in Australia, Canada, Europe, and Japan
Related Technologies: DHHS Reference No. E-181-2004/0 -- Preparation and Use of Androgenic Compounds: Nandrolone 17beta-carbonates
Portfolios: Internal Medicine Gene Based Therapies
Gene Based Therapies -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Tara L. Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4426
Email: tarak@mail.nih.gov
Fax: (301)402-0220
